Washington — More than half of postmenopausal women being treated for osteoporosis in the United States and the rest of the world have vitamin D levels that are inadequate for skeletal health, according to two recent cross-sectional surveys totaling 2,821 such women in 20 countries.

“Wherever we look in the world, patients are not getting enough vitamin D to maintain calcium homeostasis,” this is a missed opportunity. When we’re giving bone-active drugs to patients with osteoporosis, if we don’t think about vitamin D inadequacy then we miss the opportunity to ensure that our patients have optimal gains in bone mineral density. And these studies show that the problem is very, very common,” David Hosking, M.D., declared at the annual European congress of rheumatology.

The North American survey involved 1,356 community-dwelling postmenopausal women being treated for osteoporosis. Of these, 52% were found to have a serum 25-hydroxyvitamin D (25(OH)D) level below 30 ng/mL, which experts define as the cutoff for vitamin D inadequacy from the standpoint of facilitating calcium absorption in the intestine. Both surveys showed the prevalence of secondary hyperparathyroidism began rising as 25(OH)D dropped below 30 ng/mL. The body senses when intestinal calcium absorption is inadequate. It responds by triggering secondary hyperparathyroidism. The resultant increased parathyroid hormone production leads to greater bone remodeling.

If you’re young, that probably doesn’t matter desperately much, but if you’re elderly or you’re a postmenopausal woman in negative calcium balance, then that amplifies your rate of bone loss,” explained Dr. Hosking of Nottingham (England) City Hospital.

In the international survey, the overall prevalence of vitamin D inadequacy was 45%, as compared with 63% in those taking a daily supplement of at least 400 IU of vitamin D. But that 45% prevalence is still unacceptable high, Dr. Hosking said, adding that it probably reflects poor compliance with vitamin D therapy.

“In the North American survey, multivariate analysis identified eight variables as independent predictors of vitamin D inadequacy: age older than 80 years; obesity; nonwhite race; the use of drugs known to affect vitamin D metabolism; education less than 12th grade; lack of exercise; a daily vitamin D intake lower than 400 IU; and a lack of physician counseling regarding the importance of vitamin D to bone health. Patients with five or more risk factors had a 90% prevalence of inadequate vitamin D.”

Two of these risk factors—failure to take an adequate daily vitamin D supplement and lack of physician counseling regarding vitamin D’s importance to skeletal health—are readily remediable through patient and physician education. That’s the approach Dr. Hosking considers most effective. Some experts advocate modestly increasing sun exposure; however, the skin becomes less capable of converting sunlight to vitamin D with advancing age, and skin cancer is an issue.

Dr. Hosking was skeptical about taking a public health approach to encourage people to eat more vitamin D–rich foods, as the list of such foods is limited. “I think for us within osteoporosis, it’s much easier to target patients who need vitamin D supplements as part of our treatment because, after all, we’re giving them a preparation to control their bone disease, so it’s practical to deal with vitamin D at that stage,” he said.

His analysis of the survey data was funded by Merck Sharp & Dohme Ltd. He is a consultant to the company as well as a member of its speakers’ bureau.

New Cutoff Value Identifies More Vitamin D Deficiency

By Miriam E. Tucker
Senior Writer

Washington — A serum 25-hydroxyvitamin D level below 30 ng/mL appears to define vitamin D deficiency. Paraskevi Sapountzi, M.D., reported at the annual meeting of the American Association of Clinical Endocrinologists.

Vitamin D deficiency, which is highly prevalent among patients with osteoporosis, can lead to a poor response to therapy. But recent reports of assay variability have led to confusion about interpretation of the metabolite 25(OH)D levels, and not enough data are available to guide clinicians regarding when to initiate vitamin D therapy, said Dr. Sapountzi, of Loyola University, Chicago.

In a retrospective analysis of 143 female and 20 male patients who had been evaluated for low bone mass at the university’s Osteoporosis and Metabolic Bone Disease Center, the patients had a mean age of 62.5 years, a mean 25(OH)D level of 29.8 ng/mL, a mean parathyroid hormone (PTH) level of 61.7 pg/mL, a mean urine calcium level of 215.7 mg/24 hours, and a mean spine T score of –1.9. None of the subjects were on vitamin D therapy or had primary hyperparathyroidism, she said.

Initially vitamin D insufficiency was defined as a 25(OH)D level of less than 20 ng/mL, based on the lab’s reference range and data from one study suggesting that this was the cutoff below which the risk for secondary hyperparathyroidism increases. With that definition, 26.4% of the 163 patients had vitamin D insufficiency.

The 25(OH)D level was significantly correlated with PTH and with urinary calcium, with the difference between the means of PTH above and below a 25(OH)D level of 30 ng/mL being significant. At 55 ng/mL, the significance was lost. Using the new cutoff of 30 ng/mL for vitamin D deficiency raised the prevalence among the subjects to 48%, Dr. Sapountzi reported.

Osteoporosis patients with 25(OH)D levels above 30 ng/mL also showed significant differences in the urinary calcium levels of patients with 25(OH)D above and below that threshold.

Suboptimal Vitamin D Levels Often Overlooked in Osteoporosis Patients

Washington — More than half of North American women receiving treatment for osteoporosis have suboptimal serum vitamin D levels, Anne E. de Papp, M.D., and her associates reported in a poster at the annual meeting of the American Association of Clinical Endocrinologists.

Inadequate vitamin D concentrations can lead to alterations in calcium and phosphate homeostasis, secondary hyperparathyroidism, bone loss, osteoporosis, and an increased risk of fractures.

Yet data from a cross-sectional study of 1,536 postmenopausal women seen at 61 North American sites suggest that the problem is often overlooked in patients being treated for osteoporosis, said Dr. de Papp, of Merck & Co. Inc., West Point, Pa., and her associates.

The patients had a mean age of 71 years (range, 47-103 years) and a mean body mass index (BMI) of 26.4 kg/m². A total of 92% were Caucasian and 13% resided at latitude greater than or equal to 42°N (Boston), while 24% lived below 35°N (Memphis). All had been taking medication to treat or prevent osteoporosis for at least 3 months. The medications used included alendronate, calcitonin, etidronate, raloxifene, risedronate, and teriparatide.

Vitamin D supplementation at a dosage of 400 IU/day or more was reported by 59.5% of the women, while the rest were taking less.

For the entire group, the mean serum level of the active vitamin D metabolite 25-hydroxyvitamin D was 30.4 ng/mL. Most of the women (92%) had levels below 20 ng/mL, considered the minimum concentration necessary to maintain optimal serum parathyroid hormone levels (Osteoporos Int. 1997;7:439-43), while 36% had 25-hydroxyvitamin D levels below 25 ng/mL, and 18% were below 20 ng/mL, the investigators reported.

Suboptimal 25-hydroxyvitamin D concentrations were found in 63% of a women taking less than 400 IU/day of vitamin D, compared with 45% of those receiving 400 IU or more per day.

The study was funded by Merck.

—Miriam E. Tucker